MEP22608A - Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors - Google Patents
Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitorsInfo
- Publication number
- MEP22608A MEP22608A MEP-226/08A MEP22608A MEP22608A ME P22608 A MEP22608 A ME P22608A ME P22608 A MEP22608 A ME P22608A ME P22608 A MEP22608 A ME P22608A
- Authority
- ME
- Montenegro
- Prior art keywords
- nr5r6
- cycloalkyl
- alkyl
- optionally substituted
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Pronalazak se odnosi na nove proizvode formule (I) gdje p predstavlja 0 do 2. R i R1 predstavljaju O ili NH. R2 i R3 posebno predstavljaju vodonik, alkil, alkenil. alkinil, cikloalkil, aril i heteroaril koji su opcionalno supstituisani, ili alternativno R2 i R3 formiraju zajedno sa ugljenikovim atomom za koji su vezani, karbocikličnii ili heterociklični radikal, gdje ovi radikali mogu biti opcionalno supstituisani. A1 predstavlja jednostruku vezu , alkil. alil ili propinil. Y i Y1 posebno predstavljaju H, OCF3, S(0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3, -0-CHF2. -0-CH2-CF3, SF5 i S02NR5R6, sa R5 i R6 odabranim posebno od vodonika, alkil, alkenil, cikloalkil, cikloalkenil, heterocikloalkil, aril I heteroaril, koji opcionalno mogu biti supstituisani ili alternativno R5 i R6 formiraju zajedno sa N za koji su vezani, heterociklični radikal. A2 predstavlja A1, CO i S02. B2 predstavlja heterociklični radikal opcionalno supstituisan sa jednim ili više supstituenata odabranih od vrednosti za Y2. Y2 posebno predstavlja vodonik, halogen, hidroksi, cijano, alkil, alkoksi, cikloalkil, heterocikloalkil, aril, heteroaril, -O-alkenil, -O-alkinil, -O-cikloalkil, -S(0)n-alkil, -S(0)n-alkenil, -S(0)n-alkinil, -S(0)n-cikloalkil, COOR13, -OCOR13, NR5R6, CONR5R6, S(0)n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13, NH-S02-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6 ili -NR10-COOR13, gdje svi ovi radikali opcionalno mogu biti supstituisani. n predstavlja ceo broj od 0 do 2, gdje ovi proizvodi mogu biti u bilo kom izomernom obliku ili u obliku soli, kao medicinski proizvodi.The invention relates to novel products of formula (I) wherein p represents 0 to 2. R and R1 represent O or NH. R2 and R3 in particular represent hydrogen, alkyl, alkenyl. alkynyl, cycloalkyl, aryl and heteroaryl which are optionally substituted, or alternatively R2 and R3 form together with the carbon atom to which they are attached, a carbocyclic or heterocyclic radical, where these radicals may be optionally substituted. A1 represents a single bond, alkyl. allyl or propynyl. Y and Y1 in particular represent H, OCF3, S (O) nCF3, S (O) nAlk, SO2CHF2, SO2CF2CF3, -O-CHF2. -O-CH2-CF3, SF5 and SO2NR5R6, with R5 and R6 specially selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl and heteroaryl, which may be optionally substituted or alternatively R5 and R6 form together with N for which are attached, a heterocyclic radical. A2 represents A1, CO and SO2. B2 represents a heterocyclic radical optionally substituted with one or more substituents selected from the value for Y2. Y2 in particular represents hydrogen, halogen, hydroxy, cyano, alkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -O-alkenyl, -O-alkynyl, -O-cycloalkyl, -S (O) n-alkyl, -S O) n-alkenyl, -S (O) n-alkynyl, -S (O) n-cycloalkyl, COOR13, -OCOR13, NR5R6, CONR5R6, S (O) n-NR5R6, -NR10-CO-R13, -NR10 -SO2-R13, NH-SO2-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6 or -NR10-COOR13, where all of these radicals may be optionally substituted. n represents an integer from 0 to 2, where these products can be in any isomeric form or in salt form, as medicinal products.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0301098A FR2850652B1 (en) | 2003-01-31 | 2003-01-31 | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
PCT/FR2004/000188 WO2004070050A2 (en) | 2003-01-31 | 2004-01-28 | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP22608A true MEP22608A (en) | 2010-06-10 |
Family
ID=32696243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-226/08A MEP22608A (en) | 2003-01-31 | 2004-01-28 | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1599464B1 (en) |
JP (1) | JP4604020B2 (en) |
KR (1) | KR20050098286A (en) |
CN (1) | CN1768054A (en) |
AR (1) | AR042936A1 (en) |
AT (1) | ATE482207T1 (en) |
AU (1) | AU2004209319A1 (en) |
BR (1) | BRPI0407091A (en) |
CA (1) | CA2513631A1 (en) |
DE (1) | DE602004029236D1 (en) |
FR (1) | FR2850652B1 (en) |
HR (1) | HRP20050679A2 (en) |
MA (1) | MA27651A1 (en) |
ME (1) | MEP22608A (en) |
MX (1) | MXPA05007407A (en) |
NO (1) | NO20054006L (en) |
NZ (1) | NZ541270A (en) |
PE (1) | PE20040808A1 (en) |
PL (1) | PL377811A1 (en) |
RS (1) | RS20050657A (en) |
RU (1) | RU2341523C2 (en) |
TW (1) | TW200505898A (en) |
WO (1) | WO2004070050A2 (en) |
ZA (1) | ZA200505934B (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005077344A2 (en) | 2003-08-29 | 2005-08-25 | The Brigham And Women's Hospital, Inc. | Hydantoin derivatives as inhibitors of cellular necrosis |
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
AU2004305075A1 (en) | 2003-12-19 | 2005-07-07 | The Regents Of The University Of California | Methods and materials for assessing prostate cancer therapies |
NZ550102A (en) | 2004-02-24 | 2010-10-29 | Univ California | Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives) |
EP1621535A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
KR101332924B1 (en) | 2005-05-13 | 2013-11-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Diarylhydantoin compounds |
US7709516B2 (en) * | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
FR2896504B1 (en) * | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | NOVEL CYCLIC UREA DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
FR2896503B1 (en) * | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | NOVEL CYCLIC UREA SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES |
HUE027894T2 (en) | 2006-03-27 | 2016-11-28 | Univ California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
SG10201408699TA (en) | 2006-03-29 | 2015-02-27 | Univ California | Diarylthiohydantoin compounds |
RU2009108280A (en) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Arylamino-arylalkyl-substituted imidazolidine-2,4-dione, methods for their preparation containing these compounds and their use |
JP2010512389A (en) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | Aspartyl protease inhibitor |
EP2620432A3 (en) | 2007-10-26 | 2013-12-18 | The Regents Of the University of California | Diarylhydantoin compounds |
AU2009329879A1 (en) | 2008-12-23 | 2011-08-11 | President And Fellows Of Harvard College | Small molecule inhibitors of necroptosis |
EP3124481B1 (en) | 2010-02-16 | 2018-03-28 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
EP2655428B1 (en) * | 2010-12-21 | 2022-09-14 | Cytec Technology Corp. | Microdispersions of hydroxamated polymers and methods of making and using them |
US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
SG10201912719TA (en) | 2012-09-26 | 2020-02-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
JOP20200097A1 (en) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
US9725452B2 (en) | 2013-03-15 | 2017-08-08 | Presidents And Fellows Of Harvard College | Substituted indoles and pyrroles as RIP kinase inhibitors |
GB201312492D0 (en) * | 2013-07-12 | 2013-08-28 | Syngenta Ltd | Herbicidal compounds |
BR112016016289B1 (en) | 2014-01-14 | 2023-02-07 | Takeda Pharmaceutical Company Limited | HETEROARIS AND USES THEREOF |
WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
EP3229807A4 (en) | 2014-12-11 | 2018-10-17 | President and Fellows of Harvard College | Inhibitors of cellular necrosis and related methods |
TWI726969B (en) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | Substituted thiohydantoin derivatives as androgen receptor antagonists |
CN107619388A (en) * | 2016-07-13 | 2018-01-23 | 南京天印健华医药科技有限公司 | Heterocyclic compound as FGFR inhibitor |
CN109641871B (en) * | 2016-07-20 | 2021-10-22 | 诺华股份有限公司 | Aminopyridine derivatives and their use as selective ALK-2 inhibitors |
AU2018351714A1 (en) | 2017-10-16 | 2020-04-30 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
CN111542513A (en) * | 2017-10-31 | 2020-08-14 | 佩勒梅德有限公司 | Pharmaceutical composition for preventing or treating acute myelogenous leukemia or metastatic breast cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2329276A1 (en) * | 1975-10-29 | 1977-05-27 | Roussel Uclaf | NEW SUBSTITUTES IMIDAZOLIDINES, METHOD OF PREPARATION, APPLICATION AS A MEDICINAL PRODUCT AND COMPOSITIONS CONTAINING THEM |
DE4228717A1 (en) * | 1992-08-28 | 1994-03-03 | Cassella Ag | Imidazolidine derivatives |
DE19540027A1 (en) * | 1995-10-27 | 1997-04-30 | Gruenenthal Gmbh | Substituted imidazolidine-2,4-dione compounds as active pharmaceutical ingredients |
DK0966447T3 (en) * | 1997-03-03 | 2003-06-23 | Boehringer Ingelheim Pharma | Useful small molecules for the treatment of inflammatory diseases |
DE19732928C2 (en) * | 1997-07-31 | 2000-05-18 | Gruenenthal Gmbh | Use of substituted imidazolidine-2,4-dione compounds as pain relievers |
FR2796945B1 (en) * | 1999-07-30 | 2002-06-28 | Sod Conseils Rech Applic | NOVEL DERIVATIVES OF HYDANTOINS, THIOHYDANTOINS, PYRIMIDINEDIONES AND THIOXOPYRIMIDINONES, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS |
CN1209358C (en) * | 2000-05-31 | 2005-07-06 | 田边制药株式会社 | Inhibitors of alpha L beta 2 mediated cell adhesion |
CA2486090C (en) * | 2002-05-16 | 2011-07-05 | Bayer Cropscience Gmbh | Pyridine carboxamide derivatives and their use as pesticides |
-
2003
- 2003-01-31 FR FR0301098A patent/FR2850652B1/en not_active Expired - Fee Related
-
2004
- 2004-01-22 PE PE2004000090A patent/PE20040808A1/en not_active Application Discontinuation
- 2004-01-27 AR ARP040100233A patent/AR042936A1/en unknown
- 2004-01-28 CN CNA2004800088356A patent/CN1768054A/en active Pending
- 2004-01-28 AU AU2004209319A patent/AU2004209319A1/en not_active Abandoned
- 2004-01-28 WO PCT/FR2004/000188 patent/WO2004070050A2/en active Application Filing
- 2004-01-28 PL PL377811A patent/PL377811A1/en not_active Application Discontinuation
- 2004-01-28 MX MXPA05007407A patent/MXPA05007407A/en active IP Right Grant
- 2004-01-28 BR BR0407091-7A patent/BRPI0407091A/en not_active IP Right Cessation
- 2004-01-28 DE DE602004029236T patent/DE602004029236D1/en not_active Expired - Lifetime
- 2004-01-28 ME MEP-226/08A patent/MEP22608A/en unknown
- 2004-01-28 JP JP2006502123A patent/JP4604020B2/en not_active Expired - Fee Related
- 2004-01-28 EP EP04705838A patent/EP1599464B1/en not_active Expired - Lifetime
- 2004-01-28 RU RU2005127335/04A patent/RU2341523C2/en not_active IP Right Cessation
- 2004-01-28 RS YUP-2005/0657A patent/RS20050657A/en unknown
- 2004-01-28 AT AT04705838T patent/ATE482207T1/en not_active IP Right Cessation
- 2004-01-28 CA CA002513631A patent/CA2513631A1/en not_active Abandoned
- 2004-01-28 KR KR1020057014096A patent/KR20050098286A/en not_active Application Discontinuation
- 2004-01-28 NZ NZ541270A patent/NZ541270A/en unknown
- 2004-01-30 TW TW093102064A patent/TW200505898A/en unknown
-
2005
- 2005-07-22 ZA ZA200505934A patent/ZA200505934B/en unknown
- 2005-07-29 HR HR20050679A patent/HRP20050679A2/en not_active Application Discontinuation
- 2005-07-29 MA MA28417A patent/MA27651A1/en unknown
- 2005-08-29 NO NO20054006A patent/NO20054006L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2341523C2 (en) | 2008-12-20 |
PE20040808A1 (en) | 2004-12-31 |
HRP20050679A2 (en) | 2006-12-31 |
RU2005127335A (en) | 2006-09-10 |
BRPI0407091A (en) | 2006-01-24 |
MA27651A1 (en) | 2005-12-01 |
CA2513631A1 (en) | 2004-08-19 |
ATE482207T1 (en) | 2010-10-15 |
WO2004070050A2 (en) | 2004-08-19 |
FR2850652A1 (en) | 2004-08-06 |
ZA200505934B (en) | 2007-06-27 |
TW200505898A (en) | 2005-02-16 |
EP1599464A2 (en) | 2005-11-30 |
PL377811A1 (en) | 2006-02-20 |
AR042936A1 (en) | 2005-07-06 |
JP4604020B2 (en) | 2010-12-22 |
CN1768054A (en) | 2006-05-03 |
JP2006517569A (en) | 2006-07-27 |
AU2004209319A1 (en) | 2004-08-19 |
FR2850652B1 (en) | 2008-05-30 |
KR20050098286A (en) | 2005-10-11 |
RS20050657A (en) | 2007-06-04 |
EP1599464B1 (en) | 2010-09-22 |
NO20054006L (en) | 2005-10-13 |
MXPA05007407A (en) | 2005-09-12 |
NZ541270A (en) | 2008-11-28 |
NO20054006D0 (en) | 2005-08-29 |
DE602004029236D1 (en) | 2010-11-04 |
WO2004070050A3 (en) | 2005-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP22608A (en) | Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors | |
TW200617004A (en) | Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | |
NO20052993L (en) | 4,5-diarylthiazole derivatives as CB-1 ligands. | |
MXPA03010129A (en) | N-aroyl cyclic amines. | |
NO20082976L (en) | Sulfur-containing cyclic urea derivatives, their preparation and their pharmaceutical use as kinase inhibitors | |
MXPA03008754A (en) | Pyridine derivatives. | |
NO20063780L (en) | Process for the preparation of 2-aminithiazole-5-aromatic carboxamide as kinase inhibitors. | |
HUP0500339A2 (en) | Arylamines useful for the treatment of conditions associated with gsk-3, process for producing them, pharmaceutical compositions containing them and use thereof | |
NO20080456L (en) | Novel 2,4-dianilinopyrimidine derivatives, their preparation and their use as drugs, pharmaceutical compositions and, in particular, as IKK inhibitors | |
NO20061406L (en) | Organic compounds | |
SE0104140D0 (en) | Novel Compounds | |
CY1106969T1 (en) | DPP-IV SUSPENSIONS | |
NO20065830L (en) | Substituted 2-quinolyloxazoles useful as PDE4 inhibitors. | |
ME00590A (en) | N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | |
WO2004069793A3 (en) | Novel 2-substituted cyclic amines as calcium sensing receptor modulators | |
TWI256953B (en) | Pyrimidine compounds | |
ATE507229T1 (en) | CUCURBITURIL DERIVATIVES THAT ARE SOLUBLE IN WATER AND ORGANIC SOLVENTS, METHOD FOR THEIR PRODUCTION, METHOD FOR THEIR SEPARATION AND THEIR APPLICATION | |
DE60142934D1 (en) | PHARMACEUTICAL DOPAMINE-GLYCOCONJUGATE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF | |
TW200738667A (en) | Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof | |
SE0303541D0 (en) | New compounds | |
DK1517890T3 (en) | Cationically substituted diphenyllazetidinones, processes for their preparation, drugs containing these compounds and their use | |
NO20061045L (en) | imidazole | |
RS20050562A (en) | Aryl alkyl carbamate derivatives production and use thereof in therapy | |
NO20062202L (en) | Amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3,4-dihydro-2H-chromene-6-yl derivatives, processes and intermediates for their preparation, and drugs containing these compounds | |
SE0303090D0 (en) | Novel compounds |